SK92899A3 - Use of angiotensin ii antagonists to treat symptomatic heart failure - Google Patents
Use of angiotensin ii antagonists to treat symptomatic heart failure Download PDFInfo
- Publication number
- SK92899A3 SK92899A3 SK928-99A SK92899A SK92899A3 SK 92899 A3 SK92899 A3 SK 92899A3 SK 92899 A SK92899 A SK 92899A SK 92899 A3 SK92899 A3 SK 92899A3
- Authority
- SK
- Slovakia
- Prior art keywords
- carbon atoms
- alkyl
- hydrogen
- phenyl
- nhso
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3492797P | 1997-01-10 | 1997-01-10 | |
| GBGB9704197.4A GB9704197D0 (en) | 1997-02-28 | 1997-02-28 | Method for reducing mortality with an angiotensin 11 antagonist |
| PCT/US1998/000534 WO1998030216A1 (en) | 1997-01-10 | 1998-01-07 | Use of angiotensin ii antagonists to treat symptomatic heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK92899A3 true SK92899A3 (en) | 2000-08-14 |
Family
ID=26311085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK928-99A SK92899A3 (en) | 1997-01-10 | 1998-01-07 | Use of angiotensin ii antagonists to treat symptomatic heart failure |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0966282B1 (zh) |
| JP (1) | JP2000508347A (zh) |
| KR (1) | KR20000070046A (zh) |
| CN (1) | CN1249682A (zh) |
| AT (1) | ATE243515T1 (zh) |
| AU (1) | AU729881B2 (zh) |
| CA (1) | CA2277018C (zh) |
| DE (1) | DE69815822T2 (zh) |
| DK (1) | DK0966282T3 (zh) |
| EA (1) | EA199900635A1 (zh) |
| EE (1) | EE9900278A (zh) |
| ES (1) | ES2200310T3 (zh) |
| HU (1) | HUP0000108A2 (zh) |
| IL (1) | IL130599A0 (zh) |
| NO (1) | NO993399L (zh) |
| PT (1) | PT966282E (zh) |
| SK (1) | SK92899A3 (zh) |
| WO (1) | WO1998030216A1 (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1042199A (en) * | 1998-11-06 | 2000-05-29 | Boehringer Ingelheim International Gmbh | Antihypertensive medicaments containing lacidipine and telmisartan |
| SE9902597D0 (sv) * | 1999-07-06 | 1999-07-06 | Astra Ab | New use |
| SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| NZ517468A (en) | 1999-08-30 | 2004-02-27 | Aventis Pharma Gmbh | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| US6833381B2 (en) * | 2000-02-18 | 2004-12-21 | Takeda Chemical Industries, Ltd. | TNF-α inhibitors |
| JP2005126338A (ja) * | 2003-10-21 | 2005-05-19 | Boehringer Ingelheim Pharma Gmbh & Co Kg | 心不全治療剤 |
| AR078107A1 (es) * | 2009-08-31 | 2011-10-12 | Sanofi Aventis | Uso de irbesartan para la preparacion de un medicamento para la prevencion de la hospitalizacion por insuficiencia cardiaca |
| RS65037B1 (sr) * | 2013-08-26 | 2024-02-29 | Novartis Ag | Lečenje kardiovaskularnih oboljenja |
| CA3029630A1 (en) | 2016-06-29 | 2018-01-04 | Universite De Montreal | Biarylmethyl heterocycles |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9609066A (pt) * | 1995-06-07 | 1999-01-26 | Searle & Co | Antagonista aldoesterone epoxi-esteroidal e terapia de combinação de antagonista angiotensina ii para tratamento de deficiência do coração |
-
1998
- 1998-01-07 DK DK98903447T patent/DK0966282T3/da active
- 1998-01-07 EE EEP199900278A patent/EE9900278A/xx unknown
- 1998-01-07 CA CA002277018A patent/CA2277018C/en not_active Expired - Fee Related
- 1998-01-07 EA EA199900635A patent/EA199900635A1/ru unknown
- 1998-01-07 IL IL13059998A patent/IL130599A0/xx unknown
- 1998-01-07 KR KR1019997006266A patent/KR20000070046A/ko not_active Ceased
- 1998-01-07 HU HU0000108A patent/HUP0000108A2/hu unknown
- 1998-01-07 PT PT98903447T patent/PT966282E/pt unknown
- 1998-01-07 WO PCT/US1998/000534 patent/WO1998030216A1/en not_active Ceased
- 1998-01-07 AT AT98903447T patent/ATE243515T1/de active
- 1998-01-07 AU AU60218/98A patent/AU729881B2/en not_active Ceased
- 1998-01-07 DE DE69815822T patent/DE69815822T2/de not_active Expired - Lifetime
- 1998-01-07 CN CN98803141A patent/CN1249682A/zh active Pending
- 1998-01-07 EP EP98903447A patent/EP0966282B1/en not_active Expired - Lifetime
- 1998-01-07 JP JP10531200A patent/JP2000508347A/ja active Pending
- 1998-01-07 ES ES98903447T patent/ES2200310T3/es not_active Expired - Lifetime
- 1998-01-07 SK SK928-99A patent/SK92899A3/sk unknown
-
1999
- 1999-07-09 NO NO993399A patent/NO993399L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000508347A (ja) | 2000-07-04 |
| IL130599A0 (en) | 2000-06-01 |
| WO1998030216A1 (en) | 1998-07-16 |
| DE69815822D1 (de) | 2003-07-31 |
| CA2277018C (en) | 2006-10-03 |
| ES2200310T3 (es) | 2004-03-01 |
| EA199900635A1 (ru) | 2000-02-28 |
| DE69815822T2 (de) | 2004-05-06 |
| EE9900278A (et) | 2000-02-15 |
| DK0966282T3 (da) | 2003-09-29 |
| EP0966282A1 (en) | 1999-12-29 |
| ATE243515T1 (de) | 2003-07-15 |
| CN1249682A (zh) | 2000-04-05 |
| HUP0000108A2 (hu) | 2001-04-28 |
| AU729881B2 (en) | 2001-02-15 |
| AU6021898A (en) | 1998-08-03 |
| CA2277018A1 (en) | 1998-07-16 |
| NO993399L (no) | 1999-09-09 |
| NO993399D0 (no) | 1999-07-09 |
| KR20000070046A (ko) | 2000-11-25 |
| PT966282E (pt) | 2003-10-31 |
| EP0966282B1 (en) | 2003-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6201002B1 (en) | Method for reducing mortality with an angiotensin II antagonist | |
| Marino et al. | Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects | |
| JPH11228410A (ja) | イミダゾールアンジオテンシン−ii受容体拮抗薬からなる慢性腎不全治療剤 | |
| US6300356B1 (en) | Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist | |
| JP2004523569A (ja) | 抗高血圧薬とコレステロール吸収阻害薬の併用療法 | |
| SK92899A3 (en) | Use of angiotensin ii antagonists to treat symptomatic heart failure | |
| JP2009500361A (ja) | ニフェジピンおよび/またはニソルジピン並びにアンジオテンシンiiアンタゴニストからなる有効成分の組合せを含む医薬投与形 | |
| US20190241545A1 (en) | 1,3-Dihydroimidazole-2-Thione Derivatives for Use in the Treatment of Pulmonary Arterial Hypertension and Lung Injury | |
| JP2001089393A (ja) | 脳血管障害の再発予防剤および脳血管障害の後遺症の改善・進展抑制剤 | |
| US20030073705A1 (en) | Method of treatment | |
| Pereira et al. | A novel Ca²+ channel antagonist reverses cardiac hypertrophy and pulmonary arteriolar remodeling in experimental pulmonary hypertension | |
| AU2002350832B2 (en) | Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension | |
| JP2006517557A (ja) | 脳卒中発作予防のための、アセチルサリチル酸およびアンジオテンシンii拮抗薬と組み合わせたジピリダモールの使用 | |
| CZ244899A3 (cs) | Použití antagonistů receptorů angiotensinu II | |
| CN100558359C (zh) | 肾小球病治疗剂 | |
| JP2007538030A (ja) | 有機化合物の組合せ剤 | |
| KR20040032969A (ko) | 안지오텐신 ii 수용체 길항제를 함유하는 의약 조성물 | |
| JP2008133229A (ja) | 医薬組成物 | |
| KR20070084315A (ko) | 울혈성 심장기능상실 치료용 pde v 억제제의 사용 방법 | |
| JP2023524154A (ja) | 脳アミノペプチダーゼa阻害剤と、利尿薬と、全身性レニン-アンギオテンシン系の遮断薬とを含む医薬組合せ | |
| CN120571025A (zh) | 一种含有ARNi和钙离子拮抗剂的药物组合物 | |
| WO2006002983A1 (en) | Combination of organic compounds | |
| EA044411B1 (ru) | Антагонист рецептора ангиотензина ii для предотвращения или лечения системных заболеваний у котов |